New Treatment Shows Signs of Curbing Cancer Growth

New Treatment Shows Signs of Curbing Cancer Growth

John McCain receives visitors at home in Arizona after brain cancer

A new experimental anti-cancer compound significantly reduced the average tumor weight of pancreatic cancers and ovarian cancers in preliminary studies, based on data released by Propanc Health Group Corporation. In the studies, mice inoculated with tumor cells were treated with injections of PRP, a combination of two proenzymes, trypsinogen and chymotrypsinogen.
In a pancreatic cancer study, tumors treated with PRP showed 86 percent inhibition compared with controls at 26 days after treatment. In a separate ovarian cancer study, researchers observed significant reductions in average tumor weight of 54 percent and 48 percent at the highest and lowest effective PRP doses, respectively. Furthermore, several mice in treatment groups of two different dosages appeared to have no tumors on final examination.

Based on the findings, Propanc, an emerging health care company, has filed a patent to specify the target effective dose range in preparation for human studies. Propanc’s research team focuses on developing new and proprietary treatment for colorectal, pancreatic and ovarian cancers.
“We are thrilled with the results and believe it now paves the way for scientific advice meetings with regulatory agencies to determine the development pathway for human studies,” Propanc CEO James Nathanielsz said in a statement. “As a result of achieving this significant milestone, we are convinced PRP, which is a combination of two proenzymes, trypsinogen and chymotrypsinogen, could become a breakthrough treatment in the fight against aggressive tumors like pancreatic and ovarian cancers,” he added.
The early results are “conclusive that PRP is effective in these tumor models,” Dr. Julian Kenyon, Propanc’s chief scientific officer, noted. “What is seen more interesting is that it appears that tumor models with immune functioning mice show markedly increased inhibitory effects, which could possibly be attributed to the immunobiological effects of PRP, basically enhancing the immune response to assist with tumor regression,” he said. “As a result of this fine work undertaken with our pre-clinical research partners, we have identified an efficacious dose range, which we can now use to target in human studies.”
Propanc is a publicly traded company based in Australia, and has recently raised $4 million to support its research efforts

Hope For A Cure: Anti-Cancer Compound Looks Promising

Anti-Cancer “You have cancer.
For the 14 million people who are diagnosed every year with this disease, there are few words more frightening. However, there may be new hope.
According to Propanc Health Group (OTCBB: PPCH), results from a recent study for its lead product, PRP, confirm that its anti-cancer compound has the potential to fight a wide range of cancer types, such as kidney, brain, prostate, liver and lung cancers.
The findings are important because up until recently the trend with cancer treatment has been towards ever-costlier drugs aimed at ever-narrower niches on the cancer spectrum, according to an article in The UK Times last month. But recent advancements in immunotherapy and cancer genome sequencing have opened up the possibility that fewer drugs can be used to help the body fight numerous types of cancers.
PRP is a naturally derived proenzyme formulation that seeks to halt cancer progression and spreading by eradicating cancer stem cells while leaving normal stem cells unaffected.
“I have no doubt PRP represents a new therapeutic drug class with significant potential,” said Dr. Julian Kenyon, Propane’s chief scientific officer.
Dr. Kenyon said there is reason to be cautiously optimistic since his previous experience using a proenzyme treatment in the clinic on terminally ill patients suffering from a broad range of cancers helped them survive longer than anticipated, free from any severe, or serious side effects.
Propanc said it will submit a clinical trial application in the UK later this year, initially targeting patients with advanced solid tumors in Phase I, followed by pancreatic and ovarian cancers in Phase II trials. The trials will allow Propanc to qualify for orphan drug designation, which the company intends to prepare and apply for after its meeting with the Medicines and Healthcare products and Regulatory Agency (MHRA).
“Together with the enhancement of our intellectual property and plans to seek orphan drug designation, we’re at the right time to initiate discussions with potential licensing partners looking to add a new therapeutic drug class to their portfolio,” said James Nathanielsz, Propanc’s chief executive officer.
Nathanielsz added that currently the company is sufficiently capitalized to fund the early stage development of PRP.
According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers is expected to reach more than $12 billion by 2020.

3 Surprising Things You May Not Know About Chiropractors

3 Surprising Things You May Not Know About ChiropractorsThere’s probably more than three, but the biggie may be this: It takes a minimum of seven years of higher education — including clinical patient management -; to become a doctor of chiropractic. And as the not-for-profit ( notes, the required coursework includes everything from spinal analysis to nutrition to basic sciences like neurology. And, yes, ethics too.


Popular posts from this blog

How to protect our lives from heart attack

3-Best Health Benefits- Opioids for Pain Relief-New Sauna Accelerates Health and Fitness Benefits

Have Neck Pain? Try This Alternative to Opioids